GC Biopharma unveils AI-driven mRNA-LNP platform

GC Biopharma presented its in-house mRNA-LNP platform with AI-based codon optimization, boosting protein translation efficiency by over 50% versus benchmarks. The company holds 8 patents on mRNA components, and its COVID-19 vaccine candidate GC4006A is in Phase 2 trials.

• AI codon optimization raised protein translation efficiency by more than 50%
• Repeated LNP dosing in primates kept expression stable without anti-PEG antibodies
• In animal cancer vaccine studies, tumor size decreased significantly
• GC4006A is in Phase 2; cGMP mRNA-LNP production runs at the Hwasun plant